

CITATION OF PRIOR ART



RECEIVED

Sheet 1 of 6 100 J 1995

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PT-1039	APPLICATION SERIAL NO. 07/838,675
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Rudolph E. Falk, Samuel S. Asculai,	
		FILING DATE Jan. 14, 1995	GROUP 1806 121

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JK	2,583,096	01 1952	Hadidian et al			
	3,436,454	04-1969	Nouvel			
	3,887,703	06-1975	Manoussos et al			
	4,272,522	06-1981	Balazs			
	4,716,224	12-1987	Sakurai et al.			
	4,853,226	08-1989	Machida et al.			
	4,946,870	08-1990	Partain, III. et al.			

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Sub-Class	Translation
			Class	Sub-Class	YES NO
B-72117/87	12-1987	Australia			
30806/84	07-1984	Australia			
JK	0,378,852	12-1989	Europe		
JK	1,283,892	08-1972	Great Britain		
JK	2,099,826-A	12-1982	Great Britain		
JK	A-116678/88 Application	11-1989 Laid-Open-to-Public	Japan		Yes
	61-233,622	10-1986	Japan		No
JK	57-183,707	12-1982	Japan		Yes
JK	2,364,373	10-1975	Germany		Yes

KU/KOOLAN 5/10/95

FORM PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PT-1039	APPLICATION SERIAL NO. 07/838,675
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Rudolph E. Falk, Samuel S. Asculai	
		FILING DATE Jan. 14, 1995	GROUP 1806 12 61

JAN 14 1995
U.S. PATENT AND TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	<p>Alaverdyan MI, Ter-Avetisyan AT. Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemia. <i>Bulletin of Experimental Biology and Medicine</i> 1967; 64(9): 967-969.</p>
	<p>Balazs EA, Gibbs DA. The rheological properties and biological function of hyaluronic acid. In: <i>Chemistry and Molecular Biology of the Intercellular Matrix. Volumes III.</i> New York: Academic Press, 1970. PP. 1241-1253.</p>
	<p>Balazs EA, Band P. Hyaluronic acid: Its structure and use. <i>Cosmetics & Toiletries</i>. Polymers in Cosmetics 1984; 99: 65-72.</p>
	<p>Camber O, Lundgren P. Diffusion of some low molecular weight compounds in sodium hyaluronate. <i>Acta Pharmaceutica Suecica</i> 1985; 22(6): 315-320.</p>
	<p>Camber O, Edman P, Gurny R. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. <i>Current Eye Research</i> 1987; 6(6): 779-784.</p>
	<p>Chang S-C. Pro-drug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit. <i>Dissertation Abstracts International</i> 1988; 49(2): 367-B.</p>

KRUKOGLIAN 5/10/95

FORM PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PT-1039	APPLICATION SERIAL NO. 07/838,675
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Rudolph E. Falk, Samuel S. Asculai	
		FILING DATE Jan. 14, 1995	GROUP 1806 1211

<i>[Signature]</i>	Cravioto, R.O., et al. Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoid From Vitreous Humor in Depressing Blood-Sugar Levels <i>Science</i> (1950); Vol. 111: 520-521
	Gieldanowski, Jerzy; Skowronska, Jadwiga Studies on immunosuppressive and anti-inflammatory effect of adriamycin. <i>Arch. Immunol. Ther. Exp.</i> (1980); 28 (3): 439-446
	Hassan HG, Akerman B, Ranck H, Lindberg B, Lindquist B. Effects of adjuvants to local anaesthetics on their duration. <i>Acta Anaesthesiol. Scand.</i> 1985; 29: 384-388.
	Hurd ER Immunosuppressive and anti-inflammatory properties of cyclophosphamide, azathioprine and methotrexate. <i>Arthritis and Rheumatism</i> (1973 Jan-Feb); 16 (1): 84-88
	Idson B. Polymers in skin cosmetics. <i>Cosmetics & Toiletries</i> 1988; 103: 63-68.
	Johansson A, Hassan H, Renck H. Effects of adjuvants to local anaesthetics on their duration. <i>Acta Anaesthesiol. Scand.</i> 1985; 29: 736-738.
	Kalbhenn D.A. The inhibitory effects of steroid and non-steroidal antirheumatic drugs on articular cartilage in osteoarthritis and its counteraction by a biological GAG-peptide complex (Rumalon®). <i>Z. Rheumatol</i> (1982); 41: 202-211

KRT/KOREAN 5/10/95

FORM PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PT-1039	APPLICATION SERIAL NO. 07/838,675
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Rudolph E. Falk, Samuel S. Asculai	
		FILING DATE Jan. 14, 1995	GROUP 1806 1211
			

<i>[Signature]</i>	Katsu M., Abe T., Shimada S. Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence. <i>Nippon Rinsho</i> (1968 Jan); 26(1): 89-95
	Kreis H, Chkoff N, Droz D, et al. Nonsteroid anti-inflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients. <i>Transplantation</i> (1984 Feb.); 37(2): 139-145
	McIlwraith W. Current concepts in equine degenerative joint disease. <i>Journal of the American Veterinary Medical Association</i> 1982; February 1: 239-250.
	Mizushima, Y. Possibility of non-steroid anti-inflammatory drugs as a substitute for steroids-analysis of the present situation and demands for the future. <i>Nippon Rinsho</i> (Jan. 1986); 26(1): 61-65
	Nizolek DJH, White KK. Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease: A review. <i>The Cornell Veterinarian</i> 1981; 71(4): 355-375.
	Pigman W, et al. Acide hyaluronique et facteurs de perméabilité tissulaire. <i>Bull. Soc. Chim. Biol.</i> 1963; 45(2-3): 185-202.
	Pruett RC, Schepens CL, Constable JJ, Swann DA. Hyaluronic acid vitreous substitute. In: <i>Vitreous Surgery and Advances in Fundus Diagnosis and Treatment</i> . Freeman H.M., et al., Editors. Appleton-Century-Crofts, 1977: Chapter 55, pp. 433-444.

KRIKORIAN 5/10/95

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PT-1039	APPLICATION SERIAL NO. 07/838,675
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Rudolph E. Falk, Samuel S. Asculai	
		FILING DATE Jan. 14, 1995	GROUP 1806 1241

	<p>Reim M, Teping C. Surgical procedures in the treatment of most severe eye burns. <i>Acta Ophthalmologica</i> 1989-Supplementum 192; 67: 47-54.</p>
	<p>Rydell NW, Balazs EA. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. <i>Clinical Orthopaedics and Related Research</i> 1971; 80(October): 25-29.</p>
	<p>Saba P, Galeone F, Salvadorini F, Guarugnini M, Ombrato M. Investigation of the antihyperlipemic activity of an association of clofibrate and extractive mucopolysaccharide complex. <i>Current Therapeutic Research</i> 1978; 23(4): 455-463.</p>
	<p>Stegman R, Miller D. Use of sodium hyaluronate in severe penetrating ocular trauma. <i>Acta Ophthalmol.</i> 1986; 18: 9-13.</p>
	<p>Trabucchi E, Foschi D, Marazzi M, Radaelli E, Lucianetti A, Rizzitelli E, Baratti C, et al. Prevention of wound dehiscence in severely obese patients with jejunoo-ileal by-pass: The role of hyaluronic acid. <i>Pharmatherapeutica</i> 1988; 5(4): 233-239.</p>
	<p>Sertoli P, Merello A, Parodi M. L'acido jaluronico, per uso topico, nella cura delle ulcere trofocircolatorie degli arti inferiori. (Comunicazioni). <i>Giornale Italiano di Dermatologia</i> 1970; 45(8): 468-471.</p>
	<p>Walther, M. The Prevention of Striae Cutis Distansae During Pregnancy. <i>Mineva Gynecologica</i> (1981) Vol. 33: 497-499</p>

KILKORNAN 8/10/95

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PT-1039	APPLICATION SERIAL NO. 07/838,675
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Rudolph E. Falk, Samuel S. Asculai	
		FILING DATE Jan. 14, 1995	GROUP 1806 1261

<i>[Signature]</i>	Weirich, E.G., Longauer, J.K., Kirkwood, A.H. Dermatopharmacology of salicylic acid. III. Topical anti-inflammatory effect of salicylic acid and other drugs in animal experiments. <i>Dermatologica</i> (1976); 152(2): 87-99
EXAMINER <i>KP/KD/CW</i>	DATE CONSIDERED <i>5/10/95</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	